Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy.

Cheal SM, Patel M, Yang G, Veach D, Xu H, Guo HF, Zanzonico PB, Axworthy DB, Cheung NV, Ouerfelli O, Larson SM.

Bioconjug Chem. 2020 Mar 18;31(3):501-506. doi: 10.1021/acs.bioconjchem.9b00736. Epub 2020 Feb 10.

PMID:
31891487
2.

Evaluation of glycodendron and synthetically modified dextran clearing agents for multistep targeting of radioisotopes for molecular imaging and radioimmunotherapy.

Cheal SM, Yoo B, Boughdad S, Punzalan B, Yang G, Dilhas A, Torchon G, Pu J, Axworthy DB, Zanzonico P, Ouerfelli O, Larson SM.

Mol Pharm. 2014 Feb 3;11(2):400-16. doi: 10.1021/mp4003128. Epub 2013 Nov 23.

3.

Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu.

Mohsin H, Jia F, Bryan JN, Sivaguru G, Cutler CS, Ketring AR, Miller WH, Simón J, Frank RK, Theodore LJ, Axworthy DB, Jurisson SS, Lewis MR.

Bioconjug Chem. 2011 Dec 21;22(12):2444-52. doi: 10.1021/bc200258x. Epub 2011 Nov 14.

PMID:
22053899
4.

Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.

Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur DS, Gopal AK, Press OW.

Cancer Res. 2007 Jun 15;67(12):5921-8.

5.

Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.

Pantelias A, Pagel JM, Hedin N, Saganic L, Wilbur S, Hamlin DK, Wilbur DS, Lin Y, Stone D, Axworthy D, Gopal AK, Press OW.

Blood. 2007 Jun 1;109(11):4980-7. Epub 2007 Feb 15.

6.

A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.

Lin Y, Pagel JM, Axworthy D, Pantelias A, Hedin N, Press OW.

Cancer Res. 2006 Apr 1;66(7):3884-92. Erratum in: Cancer Res. 2007 Feb 1;67(3):1405.

7.

Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.

Pagel JM, Lin Y, Hedin N, Pantelias A, Axworthy D, Stone D, Hamlin DK, Wilbur DS, Press OW.

Blood. 2006 Jul 1;108(1):328-36. Epub 2006 Mar 23.

8.

Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.

Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF.

Clin Cancer Res. 2005 Nov 15;11(22):8180-5.

9.

Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.

Su FM, Beaumier P, Axworthy D, Atcher R, Fritzberg A.

Nucl Med Biol. 2005 Oct;32(7):741-7.

PMID:
16243650
10.

Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.

Forero-Torres A, Shen S, Breitz H, Sims RB, Axworthy DB, Khazaeli MB, Chen KH, Percent I, Besh S, LoBuglio AF, Meredith RF.

Cancer Biother Radiopharm. 2005 Aug;20(4):379-90.

PMID:
16114986
11.

Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.

Sato N, Hassan R, Axworthy DB, Wong KJ, Yu S, Theodore LJ, Lin Y, Park L, Brechbiel MW, Pastan I, Paik CH, Carrasquillo JA.

J Nucl Med. 2005 Jul;46(7):1201-9.

12.

Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.

Hamblett KJ, Press OW, Meyer DL, Hamlin DK, Axworthy D, Wilbur DS, Stayton PS.

Bioconjug Chem. 2005 Jan-Feb;16(1):131-8.

PMID:
15656584
13.

Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2.

Cheung NK, Modak S, Lin Y, Guo H, Zanzonico P, Chung J, Zuo Y, Sanderson J, Wilbert S, Theodore LJ, Axworthy DB, Larson SM.

J Nucl Med. 2004 May;45(5):867-77.

14.

Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.

Yao Z, Zhang M, Garmestani K, Axworthy DB, Mallett RW, Fritzberg AR, Theodore LJ, Plascjak PS, Eckelman WC, Waldmann TA, Pastan I, Paik CH, Brechbiel MW, Carrasquillo JA.

Clin Cancer Res. 2004 May 1;10(9):3137-46.

15.

Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice.

Lewis MR, Zhang J, Jia F, Owen NK, Cutler CS, Embree MF, Schultz J, Theodore LJ, Ketring AR, Jurisson SS, Axworthy DB.

Nucl Med Biol. 2004 Feb;31(2):213-23. Erratum in: Nucl Med Biol. 2004 Oct;31(7):973.

PMID:
15013487
16.

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.

Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, Goris ML, Picozzi VJ, Axworthy DB, Breitz HB, Sims RB, Ghalie RG, Shen S, Meredith RF.

Blood. 2004 Jul 1;104(1):227-36. Epub 2004 Mar 2.

PMID:
14996706
17.

Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy.

Graves SS, Dearstyne E, Lin Y, Zuo Y, Sanderson J, Schultz J, Pantalias A, Gray D, Axworthy D, Jones HM, Auditore-Hargreaves K.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3712-21.

18.

In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.

Lewis MR, Wang M, Axworthy DB, Theodore LJ, Mallet RW, Fritzberg AR, Welch MJ, Anderson CJ.

J Nucl Med. 2003 Aug;44(8):1284-92.

19.

Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.

Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, Mallett RW, Theodore LJ, Stayton PS, Press OW.

J Nucl Med. 2003 Mar;44(3):437-45.

20.

Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts.

Zhang M, Zhang Z, Garmestani K, Schultz J, Axworthy DB, Goldman CK, Brechbiel MW, Carrasquillo JA, Waldmann TA.

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1891-5. Epub 2003 Feb 4.

21.

Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.

Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Theodore LJ, Wilbur DS, Matthews DC, Press OW.

Blood. 2003 Mar 15;101(6):2340-8. Epub 2002 Nov 21.

PMID:
12446461
22.

Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.

Yao Z, Zhang M, Axworthy DB, Wong KJ, Garmestani K, Park L, Park CW, Mallett RW, Theodore LJ, Yau EK, Waldmann TA, Brechbiel MW, Paik CH, Pastan I, Carrasquillo JA.

Cancer Res. 2002 Oct 15;62(20):5755-60.

23.

Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.

Zhang M, Yao Z, Garmestani K, Axworthy DB, Zhang Z, Mallett RW, Theodore LJ, Goldman CK, Brechbiel MW, Carrasquillo JA, Waldmann TA.

Blood. 2002 Jul 1;100(1):208-16.

PMID:
12070029
24.

A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts.

Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, Johnson T, Theodore L, Yau E, Mallett R, Meyer DL, Axworthy D.

Blood. 2001 Oct 15;98(8):2535-43.

PMID:
11588052
25.

Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy.

Goshorn S, Sanderson J, Axworthy D, Lin Y, Hylarides M, Schultz J.

Cancer Biother Radiopharm. 2001 Apr;16(2):109-23.

PMID:
11385958
26.

A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy.

Schultz J, Lin Y, Sanderson J, Zuo Y, Stone D, Mallett R, Wilbert S, Axworthy D.

Cancer Res. 2000 Dec 1;60(23):6663-9.

27.

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.

Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, Stone D, Axworthy D, Fisher D, Reno J.

Cancer Biother Radiopharm. 2000 Feb;15(1):15-29.

PMID:
10740649
28.

Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.

Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su F, Hobson LJ, Beaumier PL, Fritzberg AR.

Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1802-7.

29.

Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.

Knox SJ, Goris ML, Tempero M, Weiden PL, Gentner L, Breitz H, Adams GP, Axworthy D, Gaffigan S, Bryan K, Fisher DR, Colcher D, Horak ID, Weiner LM.

Clin Cancer Res. 2000 Feb;6(2):406-14.

30.

Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin.

Breitz HB, Weiden PL, Beaumier PL, Axworthy DB, Seiler C, Su FM, Graves S, Bryan K, Reno JM.

J Nucl Med. 2000 Jan;41(1):131-40.

31.

Quantitative analysis of a synthetic peptide, NR58-3.14.3, in serum by LC-MS with inclusion of a diastereomer as internal standard.

Wilbert SM, Engrissei G, Yau EK, Grainger DJ, Tatalick L, Axworthy DB.

Anal Biochem. 2000 Feb 1;278(1):14-21.

PMID:
10640348
32.

Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody.

Graves SS, Goshorn SC, Stone DM, Axworthy DB, Reno JM, Bottino B, Searle S, Henry A, Pedersen J, Rees AR, Libby RT.

Clin Cancer Res. 1999 Apr;5(4):899-908.

33.

Simplified preformed chelate protein radiolabeling with technetium-99m mercaptoacetamidoadipoylglycylglycine (N3S-adipate).

Kasina S, Sanderson JA, Fitzner JN, Srinivasan A, Rao TN, Hobson LJ, Reno JM, Axworthy DB, Beaumier PL, Fritzberg AR.

Bioconjug Chem. 1998 Jan-Feb;9(1):108-17.

PMID:
9460553
34.
35.
36.
37.

Mechanistic studies on the metabolic activation of acetaminophen in vivo.

Hoffmann KJ, Axworthy DB, Baillie TA.

Chem Res Toxicol. 1990 May-Jun;3(3):204-11.

PMID:
2131832
38.

Covalent binding of acetaminophen to mouse hemoglobin. Identification of major and minor adducts formed in vivo and implications for the nature of the arylating metabolites.

Axworthy DB, Hoffmann KJ, Streeter AJ, Calleman CJ, Pascoe GA, Baillie TA.

Chem Biol Interact. 1988;68(1-2):99-116.

PMID:
3203411
39.

Metabolism of N-methylformamide in mice: primary kinetic deuterium isotope effect and identification of S-(N-methylcarbamoyl)glutathione as a metabolite.

Threadgill MD, Axworthy DB, Baillie TA, Farmer PB, Farrow KC, Gescher A, Kestell P, Pearson PG, Shaw AJ.

J Pharmacol Exp Ther. 1987 Jul;242(1):312-9.

PMID:
3612534
40.

Identification of the major covalent adduct formed in vitro and in vivo between acetaminophen and mouse liver proteins.

Hoffmann KJ, Streeter AJ, Axworthy DB, Baillie TA.

Mol Pharmacol. 1985 May;27(5):566-73.

PMID:
3990678
41.

Structural characterization of the major covalent adduct formed in vitro between acetaminophen and bovine serum albumin.

Hoffmann KJ, Streeter AJ, Axworthy DB, Baillie TA.

Chem Biol Interact. 1985 Feb-Apr;53(1-2):155-72.

PMID:
3995650
42.

The microsomal metabolism and site of covalent binding to protein of 3'-hydroxyacetanilide, a nonhepatotoxic positional isomer of acetaminophen.

Streeter AJ, Bjorge SM, Axworthy DB, Nelson SD, Baillie TA.

Drug Metab Dispos. 1984 Sep-Oct;12(5):565-76.

PMID:
6149906
43.

The McCarthy Scales of Children's Abilities--sex and handedness effects in 128 Scottish five-year-olds.

Tierney I, Smith L, Axworthy D, Ratcliffe SG.

Br J Educ Psychol. 1984 Feb;54 ( Pt 1):101-5. No abstract available.

PMID:
6704317
44.

Balanced rearrangements of the autosomes: results of a longitudinal study of a newborn survey population.

Tierney I, Axworthy D, Smith L, Ratcliffe SG.

J Med Genet. 1984 Feb;21(1):45-51.

45.

The personality and psycho-sexual development of boys with 47 XXY chromosome constitution.

Bancroft J, Axworthy D, Ratcliffe S.

J Child Psychol Psychiatry. 1982 Apr;23(2):169-80.

PMID:
7068790
46.

Klinefelter's syndrome in adolescence.

Ratcliffe SG, Bancroft J, Axworthy D, McLaren W.

Arch Dis Child. 1982 Jan;57(1):6-12.

47.

Trisomy 8. Report of a mosaic human male with near-normal phenotype and normal IQ, ascertained through infertility.

Chandley AC, Hargreave TB, Fletcher JM, Soos M, Axworthy D, Price WH.

Hum Genet. 1980;55(1):31-8.

PMID:
7450754
48.

What is to be done with the XYY fetus?

Ratcliffe SG, Axworthy DG.

Br Med J. 1979 Sep 15;2(6191):672. No abstract available.

49.

The Edinburgh study of growth and development in children with sex chromosome abnormalities.

Ratcliffe SG, Axworthy D, Ginsborg A.

Birth Defects Orig Artic Ser. 1979;15(1):243-60. No abstract available.

PMID:
444643

Supplemental Content

Loading ...
Support Center